Biodexa Pharmaceuticals Files Form 6-K
Ticker: BDRX · Form: 6-K · Filed: Jul 2, 2024 · CIK: 1643918
| Field | Detail |
|---|---|
| Company | Biodexa Pharmaceuticals PLC (BDRX) |
| Form Type | 6-K |
| Filed Date | Jul 2, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer
TL;DR
Biodexa Pharmaceuticals filed a 6-K on July 2nd, confirming their foreign private issuer status and 20-F filing.
AI Summary
Biodexa Pharmaceuticals Plc filed a Form 6-K on July 2, 2024, to report information for the month of July 2024. The filing indicates that the company is a foreign private issuer and will file annual reports under Form 20-F. The principal executive office is located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom.
Why It Matters
This filing provides routine updates for investors regarding Biodexa Pharmaceuticals Plc's status as a foreign private issuer and its reporting obligations.
Risk Assessment
Risk Level: low — This is a routine administrative filing (Form 6-K) that does not contain new material financial or operational information.
Key Players & Entities
- Biodexa Pharmaceuticals Plc (company) — Registrant
- July 2, 2024 (date) — Filing Date
- 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom (location) — Principal Executive Office
- Form 6-K (document) — Filing Type
- Form 20-F (document) — Annual Report Form
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information to the SEC.
What is Biodexa Pharmaceuticals Plc's principal executive office address?
Biodexa Pharmaceuticals Plc's principal executive office is located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom.
Does Biodexa Pharmaceuticals Plc file annual reports under Form 20-F or Form 40-F?
Biodexa Pharmaceuticals Plc indicates it files annual reports under cover of Form 20-F.
What is the filing date of this Form 6-K?
This Form 6-K was filed on July 2, 2024.
What is the SIC code for Biodexa Pharmaceuticals Plc?
The Standard Industrial Classification (SIC) code for Biodexa Pharmaceuticals Plc is 2834, Pharmaceutical Preparations.
Filing Stats: 264 words · 1 min read · ~1 pages · Grade level 15.2 · Accepted 2024-07-02 08:44:04
Filing Documents
- f6k_070224.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 12KB
- 0001171843-24-003764.txt ( ) — 19KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Biodexa Pharmaceuticals PLC (Registrant) Date: July 2, 2024 /s/ Stephen Stamp Stephen Stamp Chief Executive Officer, Chief Financial Officer